Depressive symptoms and the dexamethasone suppression test in parkinsonian patients

Frochtengarten, Mario Luiz; Villares, Joào; Maluf, E; Carlini, E. A.

doi:10.1016/0006-3223(87)90156-9

Cited by 17 publications

(6 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, Sroka et al 24 reported that patients with PD and an organic brain syndrome have significant cortical atrophy, and depressed patients with PD may show nonsuppression on the dexamethasone suppression test. 25 Thus, through one or a combination of several neuropathological processes (that is, serotonergic neuronal dysfunction, mesolimbic dopaminergic dysfunction, or hypercortisolaemia with secondary generalised brain atrophy), the cognitive impairment associated with depression may occur. The mechanism by which these neuropathological processes are expressed as cognitive impairment may be influenced by the nigrostriatal pathway degeneration that is inherent to PD, and in some patients, by Alzheimer type degenerative changes.…”

Section: Discussionmentioning

confidence: 99%

Cognitive impairments and depression in Parkinson's disease: a follow up study.

Starkstein

Bolduc

Mayberg

et al. 1990

Journal of Neurology, Neurosurgery & Psychiatry

122

View full text Add to dashboard Cite

The presence of depression and cognitive impairments was examined in seventy patients with Parkinson's disease (PD). Forty nine patients of this original cohort were re-examined between three and four years after the first evaluation. While both depressed and non-depressed patients showed a significant decline in cognitive function during the follow up period, intellectual decline was significantly more severe for the depressed group. Depressed patients also showed a faster rate of progression of motor signs (mainly tremor) than the non-depressed group. Patients that died during the follow up period showed significantly more cognitive impairments than patients who were alive at follow up. These findings suggest that either there may be two forms of PD: one with depression and rapid cognitive decline and one without depression and a gradual cognitive decline; or that the mechanisms of cognitive impairment in PD and depression may interact to produce a more rapid evolution in cognitive impairment among PD patients with a previous depression than among patients without a previous depression.

show abstract

Section: Discussionmentioning

confidence: 99%

Cognitive impairments and depression in Parkinson's disease: a follow up study.

Starkstein

Bolduc

Mayberg

et al. 1990

Journal of Neurology, Neurosurgery & Psychiatry

122

View full text Add to dashboard Cite

show abstract

“…-- 30 24 -- 25 In patients with TD, there were significant correlations between post-dexamethasone levels and AIMS scale ( r = 0.68; P<0.025), Simpson's scale ( r = 0.65; P(0.025) and parkinsonism scale ( r = 0.76; P<O.Ol). There were no significant differences in age, duration of illness or HAMD scores between the two groups.…”

Section: Comparison Of Dst-positive and Dst-negative Groupsmentioning

confidence: 95%

Dexamethasone suppression test, schizophrenia and movement disorder

Aleem

Kulkarni

Yeragani

1988

Acta Psychiatr Scand

View full text Add to dashboard Cite

show abstract

“…190–192 However, the clinical utility of sleep deprivation as an antidepressant treatment is limited by the fact that the benefits generally disappear when the treated patient sleeps, even if the period of sleep is short. 192–193 Attempts to prolong the benefits of sleep deprivation with medications and other interventions have met with limited success 194–195 such that sleep deprivation is not implemented as a treatment for depression in clinical practice to any significant extent, however, it continues to attract attention as a window into the pathophysiology of MDD and the mechanisms of action of antidepressant treatments. There is also a small literature related to attempts to treat MDD with chronic (3 week), in-laboratory, REM sleep deprivation which is based on the evidence that many effective antidepressant therapies suppress REM sleep.…”

Section: The Impact Of Sleep Deprivation On Psychiatric Disordersmentioning

confidence: 99%

Psychiatric Disorders and Sleep

2012

View full text Add to dashboard Cite

SYNOPSIS Psychiatric disorders and sleep are related in important ways. In contrast to the longstanding view of this relationship which viewed sleep problems as symptoms of psychiatric disorders, there is growing experimental evidence that the relationship between psychiatric disorders and sleep is complex and includes bi-directional causation. In this article we provide the evidence that supports this point of view, reviewing the data on the sleep disturbances seen in patients with psychiatric disorders but also reviewing the data on the impact of sleep disturbances on psychiatric conditions. Although much has been learned about the psychiatric disorders-sleep relationship, additional research is needed to better understand these relationships. This work promises to improve our ability to understand both of these phenomena and to allow us to better treat the many patients with sleep disorders and with psychiatric disorders.

show abstract

Depressive symptoms and the dexamethasone suppression test in parkinsonian patients

Cited by 17 publications

References 13 publications

Cognitive impairments and depression in Parkinson's disease: a follow up study.

Cognitive impairments and depression in Parkinson's disease: a follow up study.

Dexamethasone suppression test, schizophrenia and movement disorder

Psychiatric Disorders and Sleep

Contact Info

Product

Resources

About